Publications by authors named "Ridhwaanah Jacobs"
Article Synopsis
- * Next-generation vaccines like mRNA and viral vector technologies have emerged, with adenoviral vector-based vaccines showing a stronger antibody response than mRNA vaccines for COVID-19 but having some severe adverse events.
- * Adeno-associated viral vectors have been less popular due to their weaker immune response but are now being reconsidered for use as antiviral vaccines, and this review will highlight recent advancements in this area.
Article Synopsis
- * Early research suggested that rAAVs are mostly safe and induce low immune responses, but later studies revealed issues with toxicity linked to immune reactions, posing a challenge for clinical use.
- * Ongoing research aims to better understand the factors leading to rAAV toxicity and immunogenicity, which is vital for developing safer and more effective gene therapies against HBV.
Available treatment for chronic hepatitis B virus (HBV) infection offers modest functional curative efficacy. The viral replicative intermediate comprising covalently closed circular DNA (cccDNA) is responsible for persistent chronic HBV infection. Hence, current efforts have focused on developing therapies that disable cccDNA.
View Article and Find Full Text PDFArticle Synopsis
- Current vaccines and therapies for hepatitis B struggle to eliminate chronic infections, making improved treatments crucial due to high mortality from complications like cirrhosis and liver cancer.
- Recent advances in gene therapy, specifically targeting the viral DNA (cccDNA), show promise in inhibiting HBV replication through silencing and editing techniques.
- While clinical trials for synthetic RNA silencing are underway, gene editing methods like CRISPR still require further evaluation, highlighting the importance of effective delivery and precision in therapeutic strategies for HBV.